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THE DEVELOPMENT of cyclosporine (CyA) as a novel immunosuppressive 
agent has dramatically advanced orthotopic 
liver transplantation (OLT). The use of CyA 
in pediatric OLT patients has been hindered 
by a lack of information concerning the drug's 
pharmacokinetics in children and the inter-
pretation of blood concentrations during ther-
apy. OL T should have a major effect on 
CyA's absorption, distribution, metabolism, 
and excretion since CyA is fat-soluble, highly 
protein-bound, completely metabolized, and 
excreted in the bile.' Presently, two methods 
are available for measuring CyA in biological 
fluids. The two drug assays available produce 
different results2 and measure different com-
ponents of CyA activity. The primary objec-
tives of this study were (1) to examine the 
bioavailability and pharmacokinetics of CyA 
in children receiving OL Ts and (2) to examine 
the relationship between drug assay results 
and the biochemical and clinical status of the 
pediatric OL T patients. 
MATERIALS AND METHODS 
Patients 
All pediatric patients undergoing OL T procedures 
were considered eligible for the study. Blood concentra-
tions of CyA were monitored by both radioimmunoassay 
(RIA) and high-pressure liquid chromatography 
(HPLC) during therapy in 27 children. following OL T 
procedures. Blood was obtained dai Iy prior to the morning 
dose of CyA for at least the first three postoperative days, 
and then twice weekly until the patient was discharged 
from the hospital. Other information that was collected 
included the patient's weight, Cy A dosage, hematocrit, 
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WBC count, BUN and serum creatinine, direct and total 
bilirubin, alanine aminotransferase (AL T), aspartate 
aminotransferase (AST), alkaline phosphatase, and 
gamma glutamyl transferase (GGT). 
Bioavailability and Pharmacokinetics 
Bioavailability studies were conducted in II pediatric 
patients. Four patients had suspected CyA bioavailability 
problems because of low blood concentrations, and seven 
were studied during the immediate postoperative period. 
Parental consent was obtained in the children who were 
studied during the postoperative period. For those studies 
conducted during the immediate postoperative period, the 
patient received their prescribed intravenous (IV) CyA 
dosage, infused over two hours by a Harvard infusion 
pump on the first study day. Heparinized blood samples 
were obtained prior to the start of the infusion, at the end 
of the infusion. and at 4. 6, and 8 hours following the start 
of the infusion. On the second study day, the patient 
received the same IV CyA infusion. but also received an 
oral CyA dose, concurrent with the start of the infusion. 
The oral CyA liquid was diluted with chocolate milk or 
juice and administered as quickly as the patient could 
tolerate. The blood sampling on the second day followed 
the same schedule as that of the first day. The four 
additional patients with suspected bioavailability prob-
lems were initially studied while on oral CyA and were 
restudied by either adding or substituting an IV CyA dose 
at the time of an oral dose. The blood sampling protocol 
was similar to that described for the postoperative studies. 
The area under the blood concentration v time curve 
(AUC) was calculated by the trapazoidal rule. Drug 
clearance was calculated as the IV CyA dose divided by 
the ALJC (IV), and the percentage of bioavailability (F) 
was calculated as: 
AUC (IV + oral) - AUC (IV) 
F - -----------'--
AUC (IV) 
dose (IV) 
x x 100. 
dose (oral) 
CyA Assay 
Blood samples were refrigerated at 4 ·C until assayed 
(in less than seven days). HPLC assays for CyA whole 
blood concentrations were performed using minor modifi-
cations of the technique of Sawchuk and Cartier.) Only 
HPLC analysis was performed on samples for the bio-
availability and pharmacokinetic studies. The RIA for 
CyA whole blood concentrations was performed using 
material provided by Sandoz Ltd (Basel, Switzerland). 
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RESULTS 
Twenty-seven children had blood concen-
trations of CyA monitored by HPLC and RIA 
during their therapy following OL T. No clear 
relationship could be established between dose 
and blood concentration of CyA. For example. 
although all patients were started on IV CyA 
in the dose of 2 mg/kg every eight hours. the 
trough blood concentrations on postoperative 
day 2 ranged from 418 to 2.516 ng/mL by 
RIA and from 102 to 648 ng/mL by HPLC. 
Although the ratio of RIA to HPLC blood 
concentration varied considerably. four con-
sistent observations were noted. (1) An early 
elevation in the ratio of two assay results was 
observed in the first two postoperative weeks. 
The RIA-HPLC ratio at its highest point in 
the early postoperative period was 2.5: 1.0 to 
13.6:1.0. with a mean of 5.2:1.0. (2) The 
second observation was that deterioration of 
hepa tic function secondary to rejection or 
hepatic artery thrombosis frequently pro-
duced a disproportionate rise in the RIA blood 
concentration, resulting in an elevated RIA-
HPLC ratio. Nine of the 27 children demon-
strated a twofold or greater rise in the RIA-
HPLC blood concentration ratio concurrent 
with a change in the clinical status which was 
associated with an increase in serum bilirubin 
and GGT. ALT. AST. and alkaline phospha-
tase. A definitive relationship between rejec-
tion, biochemical changes, and the RIA-
HPLC relationship could not be established, 
however. (3) A high RIA-HPlC blood con-
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centration ratio is frequently associated with 
an elevated BUN level. Sixteen of the 27 
children had a BUN level greater than 40 
mg/dL. which was frequently associated with 
an RIA-HPLC ratio of greater than 4: I. This 
association was common during the immedi-
ate postoperative period. One child had an 
elevated RIA-HPLC ratio 24 days postopera-
tively that was associated with elevated BUN 
and serum creatinine levels at a time when 
serum bilirubin and liver enzymes were within 
normal limits. In this child, a reduction in 
CyA dosage was followed by a reduction in 
the BUN level and RIA-HPlC blood concen-
tration ratio. (4) In patients who remain clini-
cally stable. the ratio of RIA-HPlC blood 
concentrations stabilizes in the 1.5: 1.0 to 
3.5: 1.0 range. 
Table 1 summarizes the bioavailability 
studies performed in 11 children, following 
the OL T. Patients A through D were clini-
cally suspected to have CyA malabsorption. 
Patient A had a large T tube output of bile in 
the postoperative period, rejection, and a low 
blood CyA concentration. The CyA clearance 
was high (13.9 mL/min/kg) despite a total 
serum bilirubin of 8.2 mg/dL. Patient B had 
diarrhea and a low blood CyA concentration, 
and required an oral CyA dose of 75 mgjkg/d 
to temporarily overcome this problem. Patient 
C had received an auxiliary OlT, which was 
not functioning, and had chronic liver failure. 
Patient D had a low blood CyA level and 
acute rejection that required retransplanta-
Table 1. Bioavailability in Pediatric OL T Patients 
CyA dose Img/kgl CI_ance 
Patient Age (mol Postoperative Tima IV Oral (mL/min/kgl Bioavailability 1%) 
A (T tube) 64 4wk 4.0 13.3 13.9 <5 
B (diarrhea) 27 6wk 1.4 33.3 5.0 6 
C (failure) 51 16wk 1.6 4.7 3.0 5 
D (rejection) 47 28 wk 3.1 6.9 4.9 8 
1 34 2d 2.6 8.8 13.0 13 
2 67 9d 1.8 8.9 12.1 18 
3 52 3d 2.4 8.1 7.1 <5 
4 39 3d 1.9 8.1 1.9 <5 
5 11 2d 3.7 18.3' 8.2 <5 
6 51 3d 2.0 8.4 10.4 19 
7 36 3d 1.6 9.2 6.0 <5 
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tion. Patients I through 7 were studied during 
the immediate postoperative period. Patients 
I, 3, and 6 were studied following their first 
OL T procedure, and patients 2, 4. 5, and 7 
were studied following their second OL T. The 
mean CyA blood clearance for the seven 
patients was 8.4 mL/min/kg. The bioavail-
ability of CyA measured by HPLC was <5% 
in four of the seven patients and was ulti-
mately associated with retransplantation (two 
patients), hepatic artery thrombosis, or bowel 
perforation. The three patients with CyA 
absorption >5% in the immediate postopera-
tive period also had the highest drug clearance 
values (> 10 mL/min/kg). 
DISCUSSION 
Preliminary investigations of CyA pharma-
cokinetics have been conducted in bone mar-
row4 and kidney transplant patients.s The 
malabsorption of CyA has been noted pre-
viously in kidney transplant candidates and 
improved over time posttransplantation.5 
While the malabsorption of CyA was 
expected in the postoperative period following 
OL T, the high degree of variability was par-
ticularly notable. Two patients absorbed 
nearly 20% of CyA soon following OLT and 
could therefore be weaned from IV therapy 
relatively rapidly. The current regimen of 
early initiation of oral CyA in conjunction 
with IV CyA while monitoring trough blood 
concentrations allows a rapid conversion to 
oral therapy alone in those patients who can 
absorb the drug. 
Larger doses of oral CyA per kilogram of 
body weight may be more necessary in chil-
dren than was formerly recognized. The two 
factors that produce this requirement were an 
increased Cy A clearance in children and fre-
quent malabsorption. Our previous study in 
adult OL T patients had demonstrated a CyA 
clearance of 463.0 mL/min or 5.8 mL/min/ 
kg.6 The observation of a higher mean clear-
ance in children even in the immediate postop-
erative period is consistent with the higher 
clearance in children of other highly metabo-
lized drugs such as theophylline. The studies 
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in patients A through D confirm that eyA 
malabsorption is a problem not only immedi-
ately following OL T but during the period of 
convalescence. While the low CyA blood con-
centrations in patient A, who had a large bile 
output from the T tube, suggested a high 
biliary CyA excretion, subsequent studies 
have shown that little unmetabolized CyA 
appears in the bile.7 
The HPLC assay for CyA measures the 
parent compound, whereas the RIA detects 
both parent CyA plus metabolites. 2 Both 
assays can be used effectively for blood CyA 
monitoring but some important differences 
were observed in monitoring children follow-
ing OL T. Since a large quantity of CyA 
metabolite detected by RIA is eliminated in 
bile,' periods of poor liver function and 
decreased bile flow may produce a large dis-
crepancy (a high RIA-HPLC ratio) between 
the assays. These high RIA-HPLC ratios 
occurred primarily during the first week fol-
lowing the OL T procedure and during periods 
of diminished liver function. such as during 
rejection or following hepatic artery thrombo-
sis. Since the primary metabolites of CyA do 
not possess significant immunosuppressant 
activity in animals and have not been tested in 
humans.s the HPLC assay must be used as a 
monitoring tool in conjunction with the RIA 
during these periods of diminished liver func-
tion. The elevated BUN and serum creatinine 
levels occasionally noted with a high RIA-
HPLC blood CyA concentration ratio suggest 
the possibility of a nephrotoxic metabolite. 
While this hypothesis has not been tested. 
there is a clear advantage to having both assay 
techniques available when monitoring OL T 
patients. 
SUMMARY 
Pediatric patients undergoing OL T have 
large variations in their dosage requirement of 
CyA due to variable drug absorption and 
elimination. CyA malabsorption is common in 
the period immediately following OL T and in 
patients with problems such as diarrhea, liver 
failure, and externalized bile drainage. While 
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drug clearance is highly variable. it is gener-
ally higher in OL T children than in adults. 
and children may require larger CyA doses on 
a body weight basis. Monitoring blood con-
centrations of CyA is essential in OL T 
patients. and both the RIA and HPLC tech-
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niques are useful. However. during the imme-
diate postoperative period and during dimin-
ished hepatic function. a high ratio of RIA to 
HPLC results can be expected. Both assay 
techniques should therefore be available when 
monitoring OLT patients. 
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